Other substances

Mefloquine hydrochloride

An antimalarial drug.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Mefloquine is an antimalarial drug possibly acting on phospholipids forming toxic complexes with free heme in erythrocytic stage plasmodia (DrugBank).

Mefloquine hydrochloride on PubChem
Mefloquine hydrochloride on Wikipedia

Marketed as

MEFLOQUINE HYDROCHLORIDE or in a fixed-dose with Artesunate

Structure image - Mefloquine hydrochloride

C1CCN[C@H](C1)[C@H](C2=CC(=NC3=C2C=CC=C3C(F)(F)F)C(F)(F)F)O.Cl

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model.	Similar viruses		Two libraries of 2406 clinically approved drugs were screened for their ability to inhibit cytopathic effects on Vero E6 cells by GX_P2X (2019-nCoV related) infection	Mar/06/2020
The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators Preprint	VERO E6 cell cultures			May/21/2020
Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro Preprint In silico	VERO E6 cell cultures		synergistic effect in combination with rupintrivir	Jul/01/2020
Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2 Small molecule In vitro Screening	Vero cells	5.09		Nov/25/2020
Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate Small molecule In vitro	VERO E6 cells; IHUMI-3 SARS-CoV-2 strain	3.20	Manifested strong inhibitory activity on SARS-CoV-2 in vitro when present at expected maximum blood concentration (fixed-dose with artesunate).	Aug/13/2020
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate Preprint	Calu-3 human airway epithelial cells		higher IC50 value in Calu-3 cells than VERO E6 cells	May/12/2020
Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo Small molecule Animal model	BALB/c mice; A549 lung adenocarcinoma cells expressing ACE2; Vero E6 cells; SARS-CoV-2 strain MA15	4.32	Inhibits the production of infectious viral particles in vitro and decreases viral gene RNA levels.	Aug/19/2020
Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation Small molecule In vitro	Vero E6 cells; SARS-CoV-2 IHUMI-3 strain	4.59	The antimalarial drug inhibited SARS-CoV-2 in vitro at IC50 and IC90 similar to the concentrations reached during oral antimalarial treatment.	Sep/08/2020
Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection 3CLpro PapainLpro Enzyme assay Animal model In vitro In silico	in silico; in vitro enzyme assay; Vero E6 cells; golden Syrian hamsters; SARS-CoV-2 clinical isolate hCoV-19/Taiwan/4/2020	9.41	Inhibited SARS-CoV-2 infection in Vero E6 cells. Oral administration preceding viral challenge significantly decreased lung viral loads in golden Syrian hamsters.	Jan/15/2021

AI-suggested references

Link	Publication date
Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model	Nov/03/2022

Export (.csv)